Skip to Content
MilliporeSigma

1134379

USP

Clarithromycin

United States Pharmacopeia (USP) Reference Standard

Slide 1 of 1
Sign Into View Organizational & Contract Pricing

Select a Size

100 MG
$364.00

$364.00

List Price$455.00Save 20%
Web-Only Promotion
Check Cart for Availability
Request a Bulk Order

About This Item

Empirical Formula (Hill Notation):
C38H69NO13
CAS Number:
81103-11-9
Molecular Weight:
747.95
MDL number:
MFCD00865140
UNSPSC Code:
41116107
PubChem Substance ID:
329749411
NACRES:
NA.24

Key Documents

View All Documentation

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

grade

pharmaceutical primary standard

API family

clarithromycin

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

O[C@@H]([C@@](O)(C)[C@@H](CC)OC([C@H](C)[C@H]1O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(OC)C2)=O)[C@@H](C)C([C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3O)[C@H]1C)=O

InChI

1S/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3/t19-,20-,21+,22+,23-,24+,25+,26-,27+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1

InChI key

AGOYDEPGAOXOCK-KCBOHYOISA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
Y0000320C9742A3487
Clarithromycin United States Pharmacopeia (USP) Reference Standard

USP

1134379

Clarithromycin

Clarithromycin European Pharmacopoeia (EP) Reference Standard

Y0000320

Clarithromycin

Clarithromycin ≥95% (HPLC)

Sigma-Aldrich

C9742

Clarithromycin

Clarithromycin 96.0-102.0% (HPLC)

Sigma-Aldrich

A3487

Clarithromycin

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

-

grade

-

manufacturer/tradename

USP

manufacturer/tradename

EDQM

manufacturer/tradename

-

manufacturer/tradename

-

format

neat

format

neat

format

-

format

-

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical

application(s)

-

application(s)

-

API family

clarithromycin

API family

clarithromycin

API family

-

API family

-

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Clarithromycin USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Clarithromycin Extended-Release Tablets
  • Clarithromycin for Oral Suspension
  • Clarithromycin Tablets

Biochem/physiol Actions

Clarithromycin is a macrolide antibiotic that interferes with bacterial protein synthesis. Clarithromycin is an acid-stable version of erythromycin and is particularly effective against Gram-negative bacteria. It has a short half-life, however its metabolite, 14-hydroxy clarithromycin is nearly twice as active as clarithromycin against certain bacteria.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

comparable product

Product No.
Description
Pricing

related product

Product No.
Description
Pricing

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk_germany

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Keith A Rodvold et al.
Antimicrobial agents and chemotherapy, 47(8), 2450-2457 (2003-07-25)
The purpose of this study was to compare the concentrations of levofloxacin and azithromycin in steady-state plasma, epithelial lining fluid (ELF), and alveolar macrophage (AM) after intravenous administration. Thirty-six healthy, nonsmoking adult subjects were randomized to either intravenous levofloxacin (500
Stig Lyngbæk et al.
European journal of preventive cardiology, 21(10), 1275-1284 (2013-06-01)
Low prevalence of detectable cardiac troponin in healthy people and low-risk patients previously curtailed its use. With a new high-sensitive cardiac troponin assay (hs-cTnT), concentrations below conventional detection may have prognostic value, notably in combination with N-terminal pro-B-type natriuretic peptide
Jerry M Zuckerman et al.
Infectious disease clinics of North America, 23(4), 997-1026 (2009-11-17)
The advanced macrolides, azithromycin and clarithromycin, and the ketolide, telithromycin, are structural analogs of erythromycin. They have several distinct advantages when compared with erythromycin, including enhanced spectrum of activity, more favorable pharmacokinetics and pharmacodynamics, once-daily administration, and improved tolerability. Clarithromycin
Pedro Gutiérrez-Castrellón et al.
Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion, 64(2), 126-135 (2012-09-21)
Upper respiratory infections (URIs) are one of the most common infectious diseases in children. Macrolides had been considered one of the best options of treatment. Instead of clarithromycin is one of the macrolides most used, meta-analysis about the safety and
Chung-Su Park et al.
The American journal of gastroenterology, 109(10), 1595-1602 (2014-08-06)
Helicobacter pylori eradication rates with clarithromycin-based triple therapy are declining, and an alternative strategy is needed urgently. We sought to compare the efficacy of pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for H. pylori eradication in a region with high
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service